الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 94 |  |  |
| | | from | 94 | | |
Abstract
Ranibizumab is one of anti-vascular endothelial growth factor (anti-VEGF) that target and bind to the factor responsible for abnormal blood vessel growth. These anti-VEGF agents have been shown to reduce the burden of AMD, DME, CNV and RVO by slowing or even reversing the vision loss typically associated with these diseases.
No medical or ocular condition is an absolute contraindication for IVI, but in some cases they may affect the choice of drug used or the timing of the procedure.No established guidelines on the safety of anti-VEGF agents have been established. Intraocular inflammation is one of the main ocular adverse effects after IVI.
A transient rise in IOP can be expected. In the normotensive patient, the IOP usually returns to baseline levels without further intervention. In patients who develop dangerously high IOP spikes, the use of ocular massage, topical IOP-reducing agents, oral medication, and possibly anterior chamber tap can be used as means to reduce IOP and thereby prevent optic nerve damage and possibly central retinal artery occlusion.
Underlying glaucoma or ocular hypertension should not be considered a contraindication to IVT injection, because the damaging effects of macular disease may be irreversible and could increase the severity of vision loss when compounded with other underlying conditions.
Our study was conducted to evaluate changes in intraocular pressure following intravitreal injections of of anti-VEGF agent (Ranizumab). 40 eyes were scheduled for intravitreal ranibizumab of (0.5 mg /0.05 ml). We conclude that intra ocular pressure (IOP) was significant difference ( but still within normal range value ) in IOP measured 24 hours after injection compared to baseline and within normal level in the follow up, one week and up to 8 weeks after injection.